<DOC>
	<DOCNO>NCT00006227</DOCNO>
	<brief_summary>This phase II trial study effectiveness paclitaxel treat patient ovarian stromal cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Ovarian Stromal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate probability clinical response toxicity paclitaxel second-line chemotherapy measurable disease patient malignant tumor ovarian stroma . II . To evaluate value inhibin predict response . OUTLINE : Patients receive paclitaxel intravenously ( IV ) 3 hour day 1 . Treatment continue every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month three year , annually thereafter .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Granulosa Cell Tumor</mesh_term>
	<mesh_term>Leydig Cell Tumor</mesh_term>
	<mesh_term>Sertoli-Leydig Cell Tumor</mesh_term>
	<mesh_term>Sex Cord-Gonadal Stromal Tumors</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients diagnose histologically confirm ovarian stromal tumor ( granulosa cell tumor , granulosa celltheca cell tumor , SertoliLeydig cell tumor [ androblastoma ] , steroid [ lipid ] cell tumor , gynandroblastoma , unclassified sex cord stromal tumor , sex cord tumor annular tubule ) Patients must recurrent stromal tumor receive one prior chemotherapy regimen Patients must measurable disease defined Gynecological Oncology Group ( GOG ) Response Evaluation Criteria Solid Tumors ( RECIST ) criteria White blood count equal great 3000/mcl Granulocyte count equal great 1500/mcl Platelet count equal great 100,000/mcl Creatinine equal less 2.0 mg % Bilirubin le equal 1.5 time normal Serum glutamic oxaloacetic transaminase ( SGOT ) less equal 3 time normal Patients GOG performance grade 0 , 1 2 Patients child bear potential must negative pregnancy test must agree practice effective mean birth control Patients meet preentry requirement specify Patients must sign approve informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization Patients GOG performance grade 3 4 Patients prior invasive malignancy ( except nonmelanoma skin cancer ) evidence disease within last 5 year whose prior malignancy treatment contraindicate current protocol therapy Patients receive one prior chemotherapy regimen Patients amenable cure surgery Patients prior radiation except whose recurrent disease outside radiation port</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>